Europe
ADOCIA announces that Eli Lilly and Company (“Lilly”) filed a complaint against Adocia in the United States District Court of the Southern District of Indiana on October 9th, 2018.
HERA-CD40L Induces T-Cell-Mediated Anti-Tumor Immune Response through Activation of Antigen-Presenting Cells
Early data from ongoing Phase 1/2 clinical trial with NOX-A12 shows promising immune responses in patients
Overall, the Swiss-based Roche announced a group sales increase of 7 percent, with the Pharmaceuticals Division up 7 percent, largely driven by sales of Ocrevus, Perjeta, Alecensa and Tecentriq.
The Minnesota Attorney General is calling out Sanofi-Aventis, Novo Nordisk and Eli Lilly over alleged price gouging for insulin. This week Minnesota Attorney General Lori Swanson filed a lawsuit against the three companies over insulin price hikes.
Shares of Regeneron jumped more than 5 percent Monday after the company announced that its blockbuster drug Dupixent (dupilumab) hit the mark in two Phase III trials studying the drug as a treatment for adults with inadequately-controlled chronic rhinosinusitis with nasal polyps.
How does big pharma expand pipeline opportunities? What are the latest developments in partnering trends with Chinese investors? What innovations are most promising in rare disease and orphan drug development? These and many more industry-relevant questions will be addressed at the 24th annual BIO-Europe®, a global life science partnering event starting on November 5.
HERA-CD40L Induces T-Cell-Mediated Anti-Tumor Immune Response through Activation of Antigen-Presenting Cells
Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.
AbbVie’s Humira is the world’s best-selling drug that generated more than $18 billion for the Illinois-based company last year. This week though, the company will begin to see challenges to Humira in Europe from biosimilars developed by Amgen and Novartis, as well as others.
PRESS RELEASES